Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Airway Obstruction D000402 13 associated lipids
Stomach Ulcer D013276 75 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Stomach Diseases D013272 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Lung Diseases D008171 37 associated lipids
Sarcoidosis D012507 13 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Genital Diseases, Male D005832 3 associated lipids
Sexually Transmitted Diseases D012749 4 associated lipids
Fatty Liver D005234 48 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis D001168 41 associated lipids
Abscess D000038 13 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Osteitis D010000 10 associated lipids
Dog Diseases D004283 5 associated lipids
Osteomyelitis D010019 10 associated lipids
Coronary Disease D003327 70 associated lipids
Pancreatitis D010195 10 associated lipids
Acne Vulgaris D000152 35 associated lipids
Skin Ulcer D012883 6 associated lipids
Eyelid Diseases D005141 4 associated lipids
Multiple Myeloma D009101 13 associated lipids
Pain, Postoperative D010149 13 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Corneal Opacity D003318 3 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Crohn Disease D003424 12 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Sinusitis D012852 9 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Penile Diseases D010409 2 associated lipids
Acquired Immunodeficiency Syndrome D000163 12 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cat-Scratch Disease D002372 4 associated lipids
Birth Weight D001724 23 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Periodontitis D010518 22 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Pregnancy Complications, Infectious D011251 11 associated lipids
Toxoplasmosis D014123 9 associated lipids
Toxoplasmosis, Congenital D014125 2 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Shock, Septic D012772 11 associated lipids
Syphilis D013587 6 associated lipids
Hearing Disorders D006311 10 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Infant, Newborn, Diseases D007232 9 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Uterine Cervicitis D002575 3 associated lipids
Neutropenia D009503 15 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Urticaria D014581 13 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Respiratory Tract Infections D012141 4 associated lipids
Agammaglobulinemia D000361 4 associated lipids
Corneal Edema D015715 3 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Enteritis D004751 8 associated lipids
Leprosy D007918 8 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Retsema J et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2449865
Wondrack L et al. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. 1996 Antimicrob. Agents Chemother. pmid:8849266
Beringer P et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. 2005 Antimicrob. Agents Chemother. pmid:16304166
Ulrich M et al. Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. 2005 Antimicrob. Agents Chemother. pmid:16304181
Saiz JC and Martín-Acebes MA Reply to Iannetta et al., "Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells". 2017 Antimicrob. Agents Chemother. pmid:28839084
Girard AE et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. 1987 Antimicrob. Agents Chemother. pmid:2830841
Iannetta M et al. Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells. 2017 Antimicrob. Agents Chemother. pmid:28839081
Vallée E et al. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. 1992 Antimicrob. Agents Chemother. pmid:1324644
Merchan LM et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. 2015 Antimicrob. Agents Chemother. pmid:25385115
Mertens JC et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. 1992 Antimicrob. Agents Chemother. pmid:1324645
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Ednie LM et al. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. 1996 Antimicrob. Agents Chemother. pmid:8843313
Bonnet M and Van der Auwera P In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. 1992 Antimicrob. Agents Chemother. pmid:1329619
Koletar SL et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. 1999 Antimicrob. Agents Chemother. pmid:10582873
Cynamon MH and Klemens SP Activity of azithromycin against Mycobacterium avium infection in beige mice. 1992 Antimicrob. Agents Chemother. pmid:1329622
Koetsveld J et al. Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents. 2017 Antimicrob. Agents Chemother. pmid:28674060
Tateda K et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891128
Ng LK et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. 2002 Antimicrob. Agents Chemother. pmid:12183262
Prunier AL et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. 2002 Antimicrob. Agents Chemother. pmid:12183270
Binet R and Maurelli AT Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. 2007 Antimicrob. Agents Chemother. pmid:17908942
Collins SA et al. Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. 2017 Antimicrob. Agents Chemother. pmid:27919896
Walsh M et al. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:3038010
Starner TD et al. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. 2008 Antimicrob. Agents Chemother. pmid:17954687
Turcinov D et al. Failure of azithromycin in treatment of Brill-Zinsser disease. 2000 Antimicrob. Agents Chemother. pmid:10817744
Tsitsika A et al. Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis. 2000 Antimicrob. Agents Chemother. pmid:10817749
Bin XX et al. Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. 2000 Antimicrob. Agents Chemother. pmid:10817751
Pacifico L et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. 1996 Antimicrob. Agents Chemother. pmid:8849215
Galarza PG et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. 2010 Antimicrob. Agents Chemother. pmid:20123998
Jaruratanasirikul S et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. 1996 Antimicrob. Agents Chemother. pmid:8851625
Wong MH et al. Emergence of clinical Salmonella enterica serovar Typhimurium isolates with concurrent resistance to ciprofloxacin, ceftriaxone, and azithromycin. 2014 Antimicrob. Agents Chemother. pmid:24752251
Marvig RL et al. Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. 2012 Antimicrob. Agents Chemother. pmid:22644032
Ohtani H et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. 2000 Antimicrob. Agents Chemother. pmid:10991836
Cigana C et al. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. 2007 Antimicrob. Agents Chemother. pmid:17210769
Beale AS and Upshon PA Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin. 1994 Antimicrob. Agents Chemother. pmid:7811001
Farrell DJ et al. Results from the Solithromycin International Surveillance Program (2014). 2016 Antimicrob. Agents Chemother. pmid:27044551
Chinh NT et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. 2000 Antimicrob. Agents Chemother. pmid:10858343
Miltner EC and Bermudez LE Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10858369
Liu P et al. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. 2011 Antimicrob. Agents Chemother. pmid:21859932
Shima K et al. Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia. 2013 Antimicrob. Agents Chemother. pmid:23478971
Bermudez LE et al. Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. 1994 Antimicrob. Agents Chemother. pmid:8067766
Goodman CD et al. Chemobiosynthesis of new antimalarial macrolides. 2013 Antimicrob. Agents Chemother. pmid:23208707
Kim MK et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. 2002 Antimicrob. Agents Chemother. pmid:12234843
Allen GP and Harris KA Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. 2017 Antimicrob. Agents Chemother. pmid:28483960
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Carter G et al. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. 2004 Antimicrob. Agents Chemother. pmid:15561879
Gnarpe J et al. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8843291
Schroeck JL et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. 2015 Antimicrob. Agents Chemother. pmid:25870064
Gödeke J et al. Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa. 2013 Antimicrob. Agents Chemother. pmid:23318806
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724
Edelstein PH et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. 2001 Antimicrob. Agents Chemother. pmid:11451675